Research programme: anti-inflammatory monoclonal antibodies - Sorrento Therapeutics
Alternative Names: Anti-CGRP antibodies - Sorrento Therapeutics; Anti-PD-L1 antibodies - Sorrento Therapeutics; Anti-RAGE antibodies - Sorrento Therapeutics; STI B010X; STI-B120X; STI-B150XLatest Information Update: 28 Jun 2018
At a glance
- Originator Sorrento Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Advanced glycosylation end product receptor antagonists; Calcitonin gene-related peptide antagonists; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Jun 2018 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
- 01 May 2014 Preclinical trials in Inflammation in USA (Parenteral)